BetterLife Pharma Announces Appointment of John W. LaRocca to Board of Directors and Audit Committee

About this update from Betterlife Pharma Inc.

Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for the treatment of migraine and headache disorders, is pleased to announce the appointment of John W. LaRocca, Esq. to its Board of Directors. Mr. LaRocca will also serve as a member of the Company's Audit Committee. Mr. LaRocca is a three-decade biopharmaceutical industry executive with extensive public company seasoning across the full life-sciences lifecycle, spanning generics, branded specialty pharma, commercial biotech, and pre-commercial pipeline assets. He has served as Chief Legal Officer, Corporate Secretary, and founding Chief Compliance Officer at four NYSE- and Nasdaq-listed companies, advising boards through proxy seasons, SEC reporting cycles, contested transactions, government investigations, a U.S. Supreme Court decision, and two sell-side exits together valued at more than $1.3 billion. In the boardroom, Mr. LaRocca has served as Corporate Secretary at three Nasdaq-listed public companies — Y-mAbs Therapeutics, Aerie Pharmaceuticals, and Eagle Pharmaceuticals — where he managed the proxy process, 10-K, 10-Q and 8-K reporting cycles, Section 16 filings, at-the-market offerings, equity plan administration, and board operating practices. His experience spans mergers and acquisitions, corporate governance, securities and SEC compliance, executive compensation, enterprise risk, and healthcare regulatory and compliance matters — the full range of expertise a public-company audit committee relies on. A track record across M&A, securities, and compliance On the transactional side, Mr. LaRocca served as principal legal officer on the $930 million sale of Aerie Pharmaceuticals to Alcon Laboratories, a Novartis subsidiary, and the $412 million sale of Y-mAbs Therapeutics to SERB Pharmaceuticals, which closed in 2025 at a 105% premium. Earlier, as Deputy General counsel at Actavis, he supported the approximately $25 billion acquisition of Forest Laboratories and the approximately $8 billion acquisition of Warner Chilcott, and over his career has led more than 200 asset, intellectual property, and product transactions across buy-side, sell-side, cross-border, and post-close integration mandates. A two-time ...

View stock analysis, news, and events for Betterlife Pharma Inc.